期刊文献+

bcr-ahl融合基因反义寡核苷酸对K562细胞生长的影响 被引量:3

The effect of antisense bcr - abl oligonucleotides on the growth of K562 cells
下载PDF
导出
摘要 目的:研究 bcr-abl融合基因硫代磷酸反义寡核苷酸(Aspo)对 K562细胞生长特性的影响,探讨其在慢性粒细胞白血病(CML)基因治疗中的意义。方法:倒置显微镜下细胞活体观察;Aspo与细胞共同培养24h、48h、72h、96h及 120h,用0.4%台盼蓝染色计各处理组死活细胞数,甲基纤维素半固体培养法观察其克隆形成率的变化,流式细胞仪测定各处理组细胞P210蛋白表达变化。结果:Aspo处理后细胞仍呈克隆状生长,当 Aspo浓度达5μmol/L时,即可产生增殖抑制作用,呈一定的量效关系,其最大抑制效应时间为作用120h,当Aspo达10μmol/L时,在一定细胞浓度范围内(1×104/mL- 5× 105/mL),均有显著抑制作用,当Aspo浓度达5μmol/L以上时,K562细胞 P210蛋白表达明显下降甚至不表达。 b2a2型 Aspo对表达 b3a2型 mRNA的 K562细胞也表现出交叉抑制作用。结论:bcr-abl融合基因反义寡核苷酸对K562细胞具有特异性增殖抑制作用,在慢性粒细胞白血病基因治疗中值得深人研究。 AIM:To study the effect of bcr - abl gene antisense phosphorothioate oligonucleotides(Aspo) on K562 cell line and explore its significance in chronic myelogencous leukemia (CML) gene therapy. METHODS: Cells were exposed to oligomers, observed by inverted microscope. Cells inhibitory rate were determined by 0.4% trypan blue exclusion. CFU - K562 were cultured in 0.8% methylcellulose. P210 was measured by flow cytometry. RESULTS:K562 cells were treated with Aspo, they still grew in clone state and show antisense sequence specific and dose dependent. When the concentration of Aspo was more than 5μmol/L, the growth of cells was inhibited and P210 was down regulated or completely suppressed, and the greatest growth inhibition was at 120h. There was significant inhibition of cell proliferation in a rang of cells number from 1 × 10-4/mL to 5 × 10-4/mL after treatment with 10μmol/L Aspo. b2a2 Aspo was also effect on K562 cells which expressing b3a2 mRNA. CONCLUSION: bcr - abl Aspo has a specific growth inhibition effect on K562 cells, and worths further study in CML gene therapy.
出处 《中国病理生理杂志》 CAS CSCD 北大核心 2000年第4期342-346,共5页 Chinese Journal of Pathophysiology
关键词 BCR-ABL 慢性白血病 融合基因 K562细胞 Aspo Fusion proteins, bcr - abl Genes Oligonucleotides, antisense Cell line
  • 相关文献

参考文献2

共引文献2

同被引文献12

  • 1孙竞,周淑芸,冯茹,伍柏松.bcr/abl mRNA反义寡核苷酸对慢性粒细胞白血病Ph^+细胞的作用[J].中国实验血液学杂志,1996,4(3):285-289. 被引量:2
  • 2陆道培 童春容.慢性粒细胞白血病[A].张之南主编.血液病诊断及疗效标准[M]:第1版[C].天津:天津科学技术出版社,1991.193-200.
  • 3ClarkRE, Grzybowski J, Broughton CM, etal. Clinical use of streptolysin to facilitate antisense oligodeoxynucleotide dilivery for purging in chronic myeloid leukemia[ J]. Bone Marrow Transptant, 1999, 23(12): 1303-1308.
  • 4Skorski T, Nieborowska SM, Wlodarski P, et al. Antisense oligodeoxynucleotide combination therapy of primary chronic myelogeneous leukemia blast crisis in SCID mice[J]. Blood,1996, 88(3): 1005 - 1012.
  • 5De FabritiisP, SkorskiT, ProprisMS, etal. Effect of bcrabl oligodeoxynucleotides on the clonogenic growth of chronic myeloid leukemia cells[J]. Leukemia, 1997, 11(6): 811-819.
  • 6Tracyg LUG. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products[J]. Science, 1990, 247(4946):1079-1081.
  • 7Machiko H, Enrique JA, Adalberto B. Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cell by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-XL[J]. J Exp Med, 2000, 191(6)
  • 8Shen ZY, Shen J, Cai WJ, et al. The alteration of mitochondria is an early event of arsenic trioxide induced apoptosis in esophageal carcinoma cells[J]. Int J Mol Med, 2000, 5(2): 155-158.
  • 9Wilson H M Jr, Hyman MS, Janet SL, et al. Mechanisms of action of arsenic trioxide[J]. Cancer Res, 2002, 62: 3893-3903.
  • 10石奇珍,吕联煌.c-myb基因反义寡核苷酸对K562细胞作用的研究[J].中华血液学杂志,1999,20(7):371-372. 被引量:1

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部